Is Compounded Semaglutide Safe? What You Should Know

Quick Answer: Compounded semaglutide is not FDA-approved, so FDA has not reviewed any compounded preparation for safety, effectiveness or quality before it is sold, and it is not the same as Wegovy or Ozempic. The risks include those described on FDA-approved semaglutide labeling, such as nausea, vomiting, pancreatitis, gallbladder problems and a boxed warning about possible thyroid C-cell tumors (seen in rodents; human risk unknown), plus compounding-specific risks such as dosing errors and differences in formulation. Compounded semaglutide should not be used by anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2), or a prior serious allergic reaction to semaglutide. Whether it is appropriate for you is a licensed clinician’s decision; ask which state-licensed pharmacy prepares it and what testing covers your preparation.

Important Disclaimer: Compounded semaglutide is not FDA-approved. FDA does not verify its safety, effectiveness or quality before marketing and distinguishes compounded drugs from approved generics. This article does not establish equivalent performance to an approved semaglutide product. Discuss the specific treatment and supporting evidence with your clinician; this information is educational.

WARNING: Wegovy labeling includes a thyroid C-cell tumor warning based on rodent findings; human risk is unknown. Contraindications include personal/family medullary thyroid carcinoma, MEN 2, and known hypersensitivity to semaglutide or product ingredients. Tell your clinician about neck swelling, persistent hoarseness or swallowing problems. This approved-product label does not establish compounded-product safety.

This guide explains how compounded semaglutide is made, how compounding pharmacies are regulated, what “FDA-approved ingredient” does and doesn’t mean, the known risks, and what to look for when evaluating a provider.

What Is Compounded Semaglutide?

Compounded semaglutide is a custom-prepared version of the medication semaglutide, made by a licensed compounding pharmacy for an individual patient based on a prescription, rather than mass-manufactured by a pharmaceutical company like Novo Nordisk (maker of Wegovy and Ozempic).

Compounded semaglutide does not have FDA product approval. Nonapproval alone does not tell you which tests a particular pharmacy or researcher has performed. Ask about the evidence for the exact finished preparation.

How Compounding Works

Compounding pharmacies obtain semaglutide as a raw active ingredient (the Active Pharmaceutical Ingredient, or API) and combine it with other ingredients to prepare an injectable solution.

The process generally involves:

• Sourcing: Obtaining semaglutide API from a licensed supplier
• Formulation: Combining the active ingredient with sterile solution and any preservatives
• Sterile preparation: Preparing the medication in a controlled, cleanroom environment using aseptic technique
• Quality control: Testing consistent with the pharmacy’s category and applicable USP standards
• Packaging: Filling and labeling sterile vials

Key Differences from Brand-Name

Aspect	Brand-Name (Wegovy/Ozempic)	Compounded Semaglutide
Active Ingredient	Semaglutide (FDA-approved formulation)	Semaglutide (compounded; formulation, concentration and excipients may differ)
FDA Approval	Yes (full approval, including the finished product)	No (the finished compounded product is not FDA-approved)
Equivalence evidence	Evidence concerns the approved product	Not established by this article
Maker	Novo Nordisk	Compounding pharmacies (per individual prescription)
Pre-filled Pens	Yes	Typically vials that require manual drawing
Insurance Coverage	Sometimes (limited for weight loss)	Rarely

Why Do People Use Compounded Semaglutide?

1. Cost

Cost is a common reason people consider compounded semaglutide. For cost details, see our guide to semaglutide costs without insurance. For Boca’s current pricing, see our product page.

2. FDA-Approved Medications

FDA-approved semaglutide includes injection and oral products. See the approved-options section for product-specific labels, and ask your clinician and pharmacy about appropriate options and availability.

3. Insurance Limitations

Many insurance plans don’t cover Wegovy for weight loss or require prior authorization, high copays, or restrictive eligibility criteria.

4. Patient-Specific Clinical Need

A patient-specific prescription is one condition of the 503A framework. A tailored dose or a general statement of clinical need does not automatically satisfy every requirement. The copying restrictions and other conditions described below also matter.

FDA Regulation of Compounded Medications

Understanding Compounding Pharmacy Regulation

Compounded medications occupy a distinct regulatory space. The FDA does not approve individual compounded preparations the way it approves commercially manufactured drugs. Instead, federal and state law govern the facilities and practices of compounding pharmacies. Importantly, a facility’s registration or a pharmacy’s state license is not the same as FDA approval of the medication itself.

Legal Framework: The Drug Quality and Security Act

The 2013 DQSA amended existing 503A provisions and created 503B, the voluntary outsourcing-facility category. FDA explains these pathways.

503A Compounding

Patient-specific prescribing requirements are among the conditions for exemptions from FDA premarket approval, current good manufacturing practice (CGMP) requirements and certain labeling requirements. Other federal and state requirements still apply.

503B Outsourcing Facilities

Registered outsourcing facilities remain subject to CGMP requirements and risk-based FDA inspections. They may supply patient prescriptions or provider orders for office stock, subject to the applicable conditions. Registration does not make their compounded products FDA-approved.

Restrictions on Copies of Approved Drugs

FDA’s April 1, 2026 update explains that 503A compounders must not make essentially copies of commercially available drugs regularly or in inordinate amounts. A change producing a significant difference for an identified patient, determined and documented by the prescriber, can fall outside the copying definition. This does not waive the other requirements.

503B has separate restrictions on bulk ingredients. In that dated update, FDA states that semaglutide is absent from both its shortage list and the 503B bulks list. Describing 503B is not permission to compound semaglutide under that pathway. Prescribers and pharmacists should check current conditions for the exact preparation.

Boca works with state-licensed 503A compounding pharmacies that prepare semaglutide for an individual patient pursuant to a valid prescription, under USP <795>/<797> standards. A 503A pharmacy is a legitimate, regulated category, not a red flag. At the same time, working with a state-licensed 503A pharmacy does not mean the medication is FDA-approved or FDA-tested, and Boca does not represent that it is.

What the FDA Does and Doesn’t Do Here

The FDA does:

• Regulate the active ingredients (APIs) used in compounding
• Receive adverse-event and quality reports; reporting obligations differ by facility type, as explained below
• Set and enforce standards that compounding pharmacies must meet under the law

The FDA does not:

• Approve individual compounded formulations for safety and effectiveness
• Routinely test compounded medications before they reach patients
• Guarantee that a compounded drug is equivalent to an FDA-approved version

503A Compounding Pharmacies

Boca works with WellSync and other state-licensed 503A compounding pharmacies in the WellSync network. Under 503A, a licensed pharmacy compounds medication for an individual patient based on that patient’s valid prescription: a prescriber makes a clinical determination for an individual patient, and the pharmacy prepares that patient’s medication under USP <795>/<797> standards.

A state pharmacy license is a sign that the pharmacy is operating within a regulated framework; it is not FDA approval of the product, and it is not a substitute for it. A 503A pharmacy is a legitimate, regulated category. Working with one does not mean the medication is FDA-approved or FDA-tested, and Boca does not represent that it is.

Quality and Safety Standards

Ingredient and Supplier Records

Ask the dispensing pharmacy to identify the active ingredient, manufacturer and lot used in your preparation. FDA explains that drug-establishment registration and listing do not establish product approval or verification of the submitted information.

A Certificate of Analysis should be read in context: which material and lot does it cover, which tests were performed, and who issued it? An ingredient report is not a test of the finished medication dispensed to you. Ask the pharmacist how supplier qualifications and ingredient records support the exact preparation.

Sterile Compounding Requirements

Injectable medications like semaglutide must be prepared under sterile conditions consistent with USP Chapter <797> (Source: USP), which addresses:

• Controlled cleanroom environments: Strict air-quality and particle-count controls
• Aseptic technique: Procedures designed to prevent contamination
• Air filtration: High-efficiency filtration to reduce particles and microorganisms
• Validated processes and environmental monitoring: Documented, monitored procedures
• Personnel training: Training and competency assessment for staff

Quality Control Testing

Testing requirements and methods depend on the preparation and applicable standards. USP’s sterile-compounding FAQ distinguishes requirements by preparation category, starting components and beyond-use date.

Sterility Testing

A sterility test evaluates sampled units. USP cautions that it does not guarantee sterility of the entire batch. Ask about the tested lot, sampling and results, alongside the pharmacy’s preparation process and contamination controls.

Endotoxin Testing

This evaluates bacterial endotoxins, which are a different concern from living microorganisms. Ask which requirements and limits apply to the preparation; sterility and endotoxin tests are not interchangeable.

Potency Testing

Ask how the measured concentration compares with the labeled strength, whether the method is suitable for the formulation and whether the report covers the finished preparation’s lot.

pH and Particulate Assessment

Ask which physical-quality checks were performed and how the results compare with the preparation’s specifications. A report or normal appearance alone does not establish the safety of every vial.

Is It the Same Medication?

Active Ingredient

A compounded preparation is a different finished product. FDA warns against semaglutide sodium and semaglutide acetate in compounding: these are different active ingredients from the one used in approved drugs, and FDA states it is unaware of a lawful basis for using them in compounding. Ask the pharmacist to identify the exact ingredient and preparation; a supplier document does not confer FDA product approval.

A compounded preparation is not an FDA-approved generic. This article does not establish that it can be substituted for Wegovy or Ozempic with the same safety, effectiveness or exposure to the drug. Any comparison requires evidence for the exact preparation and outcome.

Overall Formulation: Different

The inactive ingredients depend on the specific presentation:

• Ozempic injection lists disodium phosphate dihydrate, propylene glycol, phenol and water for injection, with pH adjustment as needed.
• Wegovy labeling distinguishes its single-dose injections from the FlexTouch presentation and tablets. Phenol and propylene glycol are included in FlexTouch; the ingredient lists should not be treated as identical across all Wegovy presentations.
• Rybelsus and Ozempic tablets have oral formulations and their own administration instructions.

For a compounded preparation, obtain the exact ingredient list, concentration and container information from the dispensing pharmacy. A generic list of possible preservatives or diluents does not establish what your vial contains or whether it is appropriate for you.

Why the Difference Matters

• Storage and dating: Use the exact preparation’s instructions and applicable discard limits; a general duration cannot establish its stability
• Consistency: Formulations can differ between compounding pharmacies
• Dosing: Follow the exact presentation’s instructions; tablets, different injection devices and compounded vials require different administration guidance
• Evidence scope: Formulation differences and their clinical effects require product-specific appraisal; FDA nonapproval alone does not establish what has or has not been studied

Effectiveness: What the Evidence Does and Doesn’t Show

No Equivalence Has Been Established

This article has not established comparable safety or effectiveness for a specific compounded preparation. A claim about the absence of all head-to-head or bioequivalence studies would require a separate literature assessment; FDA nonapproval does not establish that absence.

Clinical-Trial Results Apply to the Approved Product

Published weight-loss figures (for example, the average results often cited for semaglutide) come from clinical trials of the FDA-approved products (Wegovy and Ozempic). These trial results may not apply to compounded semaglutide, which was not studied in those trials and is a different, non-FDA-approved formulation.

Patient Reports Are Anecdotal

Some clinicians and telehealth programs share patient experiences with compounded semaglutide. These reports are anecdotal and are not controlled clinical evidence. They do not establish that compounded semaglutide is equivalent in safety or effectiveness to the brand-name products.

Factors That Can Affect an Individual’s Results

• Actual potency: If not properly tested, a compounded preparation may contain more or less semaglutide than labeled
• Stability: Improper storage or use past the beyond-use date may reduce potency
• Patient technique: Drawing from a vial requires accurate measurement; errors can cause under- or over-dosing
• Storage: Semaglutide requires refrigeration; improper storage can affect the medication

For general information on expected timelines for the medication, see our week-by-week guide, keeping in mind those figures reflect the FDA-approved products.

Potential Risks of Compounded Semaglutide

Approved semaglutide labeling describes digestive side effects and serious risks. The following actions draw on Wegovy’s Medication Guide; your clinician must also assess the exact compounded preparation.

• Possible severe allergic reaction: Stop the suspected medication and call 911 for trouble breathing or swelling of the tongue or throat. Anaphylaxis requires emergency care.
• Severe abdominal pain that persists, possibly extending to the back, with or without vomiting: stop treatment and contact your clinician immediately for possible pancreatitis.
• Persistent nausea, vomiting or diarrhea: Contact your clinician promptly; fluid loss can cause kidney problems.
• Upper abdominal pain, fever, jaundice or pale stools: Contact your clinician for possible gallbladder problems.

Discuss low-blood-sugar monitoring, particularly if you use insulin or a sulfonylurea. These examples are not a complete safety checklist. For other symptoms or uncertainty about a dose, contact your prescriber and pharmacist. The preparation-related risks below require additional assessment.

1. No FDA Product Approval

Risk: The finished compounded product lacks FDA approval. This article does not establish equivalent safety or effectiveness to Wegovy or Ozempic.

What helps: Use a licensed pharmacy and a licensed prescriber, and understand the difference between an FDA-approved drug and a compounded preparation.

2. Quality Variability

Risk: Compounding pharmacies do not all maintain the same standards; some may have weaker controls or testing.

What helps: Choose a state-licensed pharmacy that follows USP <797> and documents its quality controls.

3. Contamination

Risk: Improper sterile technique can lead to bacterial or fungal contamination and serious infection.

What helps: Ask the pharmacist about contamination controls and applicable testing for your preparation. A passing sample result does not guarantee the whole batch is sterile.

4. Potency Issues

Risk: A preparation may contain more or less semaglutide than labeled, affecting results or side effects.

What helps: Ask for the relevant finished-preparation testing information and have the pharmacist explain what it establishes. An ingredient Certificate of Analysis is not a finished-product potency result.

5. Dosing Errors

Risk: Drawing from a vial requires accurate measurement; errors can cause incorrect dosing.

What helps: FDA advises confirming how to measure the prescribed dose with your provider or compounder. Concentrations and syringe sizes can differ. Have the pharmacist confirm the dose, volume and syringe markings for your exact vial before injecting; do not copy another patient’s unit instructions.

6. Counterfeit or Adulterated Products

Risk: Some online sources sell counterfeit products, products with no active ingredient, or products containing harmful substances.

What helps: Only obtain medication through a licensed pharmacy and a valid prescription; avoid unverified international or “research-only” sources.

7. Limited Long-Term Data on Compounded Formulations

Risk: Findings about the semaglutide molecule or an approved product do not by themselves validate a specific compounded formulation.

What helps: Work with your provider, report any unexpected reactions, and understand the limits of available data.

What to Look For in a Compounding Pharmacy

If you and your prescriber decide compounded semaglutide is appropriate, the following are things to look for, not a guarantee of any outcome. For approval status, see our guide on whether compounded semaglutide is FDA-approved.

Things to Look For

1. Active State Pharmacy License: Current licensure in good standing with the state board of pharmacy
2. Valid Prescription Required: The pharmacy compounds for an individual patient based on a valid prescription from a licensed provider
3. USP <795>/<797> Compliance: Follows applicable USP standards for non-sterile and sterile compounding
4. Sterility and Potency Testing: Performs and documents appropriate testing for injectable preparations
5. Ingredient Documentation: Identifies the manufacturer, ingredient and lot; explains the applicable quality specifications and evidence
6. Documentation on Request: Willing to share quality documentation, such as a Certificate of Analysis

Additional Quality Indicators

• Accreditation: Voluntary accreditation such as PCAB can indicate a commitment to quality standards
• Transparency: Willingness to share test results and quality documentation
• Regulatory History: Review the exact findings, affected products and follow-up actions; absence of a listed action does not verify safety
• Provider Involvement: Works with licensed healthcare providers for prescriptions and monitoring
• Proper Labeling: Clear labels with strength, beyond-use date, lot number, and storage instructions

Questions to Ask

• “Are you a state-licensed compounding pharmacy in good standing?”
• “Do you compound based on a valid, patient-specific prescription?”
• “Do you follow USP <797> for sterile compounding?”
• “Do you perform sterility and potency testing, and can you provide a Certificate of Analysis?”
• “Where do you source your semaglutide API?”
• “What is the beyond-use date of the compounded semaglutide?”

Red Flags to Avoid

Warning Signs of Unsafe Sources

Be cautious of sources that:

• ❌ Are not licensed pharmacies in the United States
• ❌ Ship from outside the United States with no verifiable oversight
• ❌ Don’t require a valid prescription from a licensed provider
• ❌ Can’t or won’t provide verification of testing or quality documentation
• ❌ Cannot explain relevant regulatory findings or identify whether your medication is affected by a recall or safety alert
• ❌ Refuse to answer questions about quality and safety
• ❌ Make unrealistic promises (“lose 50 pounds in 2 months guaranteed”)
• ❌ Sell “research-only” or non-pharmaceutical-grade material for human use
• ❌ Don’t use refrigerated shipping for a medication that must be kept cold

Specific Concerns with Online Sources

• Unregulated websites: Sites selling “semaglutide” without verifying it comes from a licensed pharmacy and a valid prescription
• Research-chemical suppliers: Sources selling semaglutide “for research purposes only” (not for human use)
• Unverified international suppliers: Sellers outside any verifiable regulatory oversight
• Counterfeit products: Products labeled as semaglutide that contain little or no active ingredient

Cost vs Quality Considerations

Price Is Not a Safety Test

You may hear that very low prices (for instance, around $100/month) are a sign of a low-quality product. In our view, an unusually low price can be one reason to ask more questions, but it is an opinion and a prompt to investigate, not a safety rule. Price alone does not tell you whether a product is safe, accurately dosed, or properly tested. A low price doesn’t prove a product is unsafe, and a high price doesn’t prove a product is safe.

What matters more than the number is whether the medication comes from a state-licensed pharmacy, based on a valid prescription, with appropriate sterility and potency testing and quality documentation.

For Boca’s current pricing, please see our product page.

Value Beyond Price

Factor	Why It Matters
State Licensure	Pharmacy operates within a regulated framework
Valid Prescription	Compounding tied to an individual patient’s clinical need
Testing	Supports sterility and labeled potency
Medical Oversight	Appropriate dosing and monitoring
Transparency	Access to quality documentation

Our compounded semaglutide program works with state-licensed 503A compounding pharmacies that prepare medication for an individual patient under USP <795>/<797> standards, with licensed provider oversight and quality documentation available on request. Compounded semaglutide is not FDA-approved and has not been shown to be equivalent to Wegovy or Ozempic.

FDA-Approved Semaglutide Information

FDA-Approved Options

Approved semaglutide products include Wegovy injections and tablets, Ozempic injection, and Rybelsus and Ozempic tablets. Their indications, doses, ingredients and administration instructions differ. A labeled presentation is not a claim of local availability or suitability for every patient.

Important Considerations

• FDA-approved products: Review the exact product and presentation’s prescribing information linked above
• Clinical-trial data: Published weight-loss results from clinical trials apply to the FDA-approved products and may not apply to compounded semaglutide
• Talk to your provider: Discuss all options, including FDA-approved treatments, with a licensed healthcare provider

Frequently Asked Questions

Is compounded semaglutide FDA-approved?

No. Compounded semaglutide is not FDA-approved, and FDA does not verify its safety, effectiveness or quality before marketing. A pharmacy license, facility registration or ingredient record is not approval of the finished medication.

Is compounded semaglutide as effective as Wegovy or Ozempic?

This article does not establish equivalent safety or effectiveness for a compounded preparation. Compare the actual formulation, methods and outcomes of any cited research. Individual patient experiences cannot establish a controlled comparison.

How can I evaluate a compounding pharmacy?

Verify the dispensing pharmacy’s license with its state board and contact the pharmacy directly about your prescription. Ask which standards and tests apply to the exact preparation, what its records cover, and whether there are relevant warning letters or recalls. Licensure and test documents do not guarantee an individual vial’s safety.

What is a 503A compounding pharmacy?

503A compounding pharmacies prepare medication for an individual patient based on a valid prescription, under state-board oversight and USP <795>/<797> standards. A state pharmacy license indicates the pharmacy operates within a regulated framework; it does not mean the compounded medication is FDA-approved. Boca works with WellSync and other state-licensed 503A compounding pharmacies in the WellSync network.

Can I use compounded semaglutide if I have insurance?

Insurance typically doesn’t cover compounded medications, even when it would cover the brand-name product. Compounded semaglutide is generally a self-pay option.

How long does compounded semaglutide last?

There is no single storage duration established here for all compounded semaglutide preparations. USP’s sterile-compounding FAQ explains that beyond-use dates depend on the preparation and relevant stability, sterility and storage conditions. Refrigerating a preparation later does not extend its original assigned limit.

For compounded GLP-1 multidose vials, FDA advises disposal within 28 days after first use, even if medication remains or the compounder gives a longer interval. An earlier applicable discard date still matters. Use a new sterile needle and syringe for each dose.

Ask the pharmacist for your preparation’s exact storage and discard instructions. FDA advises against using injectable GLP-1 medication that arrives warm or without sufficient refrigeration; contact the pharmacy before using a shipment with a suspected temperature problem.

What FDA-approved options are available?

Options include the injection and oral products listed in FDA-Approved Semaglutide Information. Your clinician should match the product and indication to your medical needs. Do not substitute products or convert doses yourself. See our comparison guide for more about GLP-1 medications.

Have there been FDA safety actions involving compounded semaglutide?

Yes. In a November 1, 2024 alert about Fullerton Wellness, FDA described sterility concerns and a complaint about black particulate in a semaglutide vial. FDA instructed patients to stop using drugs from that facility and contact their healthcare professional. This is a specific safety alert, not evidence that every compounded preparation has the same problem.

Use FDA’s compounding actions page to locate inspection, warning and recall records. Ask your pharmacy to match any notice to your exact manufacturer, preparation and lot, and follow the notice’s instructions. A recall, inspection observation and warning letter are different records; inspect the relevant finding and follow-up.

How are adverse events reported?

FDA reports that adverse events involving compounded GLP-1 drugs are likely underreported. State-licensed pharmacies that are not outsourcing facilities are not required by federal law to submit these reports to FDA. A report does not by itself establish that the drug caused the event, and report counts alone are not complication rates.

Patients and clinicians can report suspected reactions and medication errors through the MedWatch pathway in FDA’s semaglutide dosing alert. Reporting does not replace medical care.

How do I know if the semaglutide is pharmaceutical-grade?

Ask the pharmacy to identify the ingredient, manufacturer, lot and applicable specifications, and to explain the supporting records. Registration and an ingredient Certificate of Analysis do not by themselves establish the quality of a finished vial. See Ingredient and Supplier Records for the distinctions.

Is it safe to switch between compounded and brand-name semaglutide?

Talk with your prescriber before switching. Do not assume different formulations will perform the same way. Ask about the evidence for the exact preparation and the dose and monitoring appropriate to your situation.

Does a lower price mean a product is unsafe?

Not necessarily. Price is not a safety test. An unusually low price can be a reason to ask more questions, but it is not proof of anything on its own. Focus on whether the medication comes from a state-licensed pharmacy, based on a valid prescription, with appropriate testing and documentation.

Conclusion: Making an Informed Choice

Compounded semaglutide is a different finished preparation without FDA product approval. This article does not establish equivalence to Wegovy or Ozempic. Assess the actual evidence for a proposed preparation with your clinician; nonapproval is not proof that no research exists.

If you and a licensed prescriber decide compounded semaglutide is appropriate for your individual clinical situation, the following can help you evaluate a source:

• ✅ Confirm the pharmacy is state-licensed and in good standing
• ✅ Make sure compounding is based on a valid, patient-specific prescription
• ✅ Confirm USP <797> compliance and appropriate sterility and potency testing
• ✅ Check pharmaceutical-grade API sourcing
• ✅ Review any warning letters or recall history
• ✅ Work with a licensed provider for prescribing and monitoring
• ✅ Ask questions and expect transparent answers

Be cautious of:

• ❌ Unlicensed sources or sellers with no verifiable oversight
• ❌ Sources that don’t require a valid prescription
• ❌ Sources that can’t document testing or quality
• ❌ “Research-only” or non-pharmaceutical-grade material sold for human use

Our compounded semaglutide program works with state-licensed 503A patient-specific compounding pharmacies that prepare medication under USP <795>/<797> standards, with:

• Licensed healthcare provider oversight and consultations
• Pharmaceutical-grade semaglutide from FDA-registered API suppliers
• Sterility and potency testing with quality documentation available on request
• Transparent information about how the medication is prepared

Compounded semaglutide is not FDA-approved and has not been shown to be equivalent to Wegovy or Ozempic. For current pricing, see our product page. For more on how semaglutide works and what to expect, visit our complete semaglutide guide.

---

Medical Disclaimer: This article is for educational purposes only and does not constitute medical or legal advice. Compounded medications are not FDA-approved and should only be used under the supervision of a licensed healthcare provider. Individual safety and effectiveness may vary, and reports of patient experience are anecdotal. Always verify the quality and source of any compounded medication, and discuss FDA-approved options with your clinician before starting treatment.

Regulatory Disclaimer: Compounded semaglutide and tirzepatide are not FDA-approved. FDA does not verify their safety, effectiveness or quality before marketing. This article does not establish equivalence to approved products. Pharmacy licensure and facility registration are not FDA product approval. Regulatory sources have dates and should be checked for subsequent changes.